You are here: Industry Insights > Market News

News List

Ultragenyx and Kyowa Kirin International announce Marketing Authorisation Application for KRN23 pharmaasia
January 23, 2017
Since August 2013, Ultragenyx and Kyowa Hakko Kirin entered into a collaboration and license agreement to develop and commercialise KRN23.
3 Biotechs That Could Peak in 2017 BioSpace.com
January 22, 2017
Biotech stocks have taken a beating in 2016 and even the “Trump Bump” for pharma stocks was short-lived. But, a new year brings new hope for investors. A Motley Fool analyst thinks he has three stocks that could “shine” next year.
Shire refiles ADHD drug pharmatimes
January 22, 2017
Shire has refiled its experimental attention deficit hyperactivity disorder drug SHP 465 in the US, having garnered new data further backing its safety and efficacy.
Asia-Pacific flu market to hit $1.71bn by 2022 pharmafile
January 22, 2017
According to new data from intelligence provider GBI Research, the flu vaccines market in the Asia-Pacific (APAC) region is set to grow from $1.24 billion in 2015 to more than $1.71 billion in 2022.
First of its kind cancer stem cell research unlocks clues to treatment resistance firstwordpharma
January 22, 2017
Study data published in the journal Oncotarget suggest that a molecule lost from cancer stem cells, called miR-17, is important in driving oesophageal tumour resistance to radiotherapy, ScienceDaily reported.
ChemoCentryx Announces Presentation of Data from Ongoing Phase Ib Clinical Trial of CCR2 Inhibitor C firstwordpharma
January 22, 2017
ChemoCentryx, Inc., announced the presentation of results from its immuno-oncology program at the American Society of Clinical Oncology (ASCO) 2017 Gastrointestinal Cancers Symposium being held January 19-21, 2017 in San Francisco, California.
Bristol-Myers Squibb won't seek accelerated US approval of Opdivo, Yervoy combination in first-line firstwordpharma
January 22, 2017
Bristol-Myers Squibb announced that it will not pursue an accelerated regulatory pathway for the combination of Opdivo (nivolumab) plus Yervoy (ipilimumab) in first-line lung cancer in the US based on a review of current data.
Bristol-Myers Squibb, Ono settle patent lawsuit with Merck & Co. regarding Keytruda firstwordpharma
January 22, 2017
Bristol-Myers Squibb and Ono Pharmaceutical on Friday announced that they have reached an agreement with Merck & Co. to settle patent-infringement litigation regarding the latter's PD-1 antibody Keytruda (pembrolizumab).
Verastem Announces Executive Leadership Appointments and Changes americanpharmaceuticalreview
January 22, 2017
Verastem, Inc., focused on discovering and developing drugs to treat cancer, announced that Hagop Youssoufian, MSc, MD, has been appointed Head of Hematology and Oncology Development.
Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer americanpharmaceuticalreview
January 22, 2017
Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer